BEAUTY HEALTH CO/THE (SKIN)
US88331L1089 - Common Stock
Taking everything into account, SKIN scores 3 out of 10 in our fundamental rating. SKIN was compared to 37 industry peers in the Personal Care Products industry. SKIN scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. SKIN is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year SKIN was profitable.
In the past year SKIN had a positive cash flow from operations.
SKIN had negative earnings in 4 of the past 5 years.
In the past 5 years SKIN reported 4 times negative operating cash flow.
1.2 Ratios
The Return On Assets of SKIN (-10.77%) is worse than 70.27% of its industry peers.
The Return On Equity of SKIN (-168.55%) is worse than 78.38% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -10.77% | ||
| ROE | -168.55% | ||
| ROIC | N/A |
ROA(3y)-12.38%
ROA(5y)N/A
ROE(3y)-88.69%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Gross Margin of SKIN (48.49%) is comparable to the rest of the industry.
In the last couple of years the Gross Margin of SKIN has declined.
SKIN does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 48.49% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.92%
GM growth 5YN/A
2. Health
2.1 Basic Checks
SKIN does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for SKIN has been reduced compared to 1 year ago.
Compared to 1 year ago, SKIN has a worse debt to assets ratio.
2.2 Solvency
SKIN has an Altman-Z score of 0.40. This is a bad value and indicates that SKIN is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of 0.40, SKIN is doing worse than 78.38% of the companies in the same industry.
SKIN has a debt to FCF ratio of 84.86. This is a negative value and a sign of low solvency as SKIN would need 84.86 years to pay back of all of its debts.
SKIN's Debt to FCF ratio of 84.86 is in line compared to the rest of the industry. SKIN outperforms 43.24% of its industry peers.
A Debt/Equity ratio of 12.43 is on the high side and indicates that SKIN has dependencies on debt financing.
Looking at the Debt to Equity ratio, with a value of 12.43, SKIN is doing worse than 89.19% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 12.43 | ||
| Debt/FCF | 84.86 | ||
| Altman-Z | 0.4 |
ROIC/WACCN/A
WACC7.7%
2.3 Liquidity
SKIN has a Current Ratio of 6.07. This indicates that SKIN is financially healthy and has no problem in meeting its short term obligations.
SKIN has a better Current ratio (6.07) than 91.89% of its industry peers.
A Quick Ratio of 5.28 indicates that SKIN has no problem at all paying its short term obligations.
The Quick ratio of SKIN (5.28) is better than 91.89% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 6.07 | ||
| Quick Ratio | 5.28 |
3. Growth
3.1 Past
The earnings per share for SKIN have decreased strongly by -51.52% in the last year.
Looking at the last year, SKIN shows a quite strong growth in Revenue. The Revenue has grown by 8.81% in the last year.
Measured over the past years, SKIN shows a very strong growth in Revenue. The Revenue has been growing by 49.50% on average per year.
EPS 1Y (TTM)-51.52%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q-240%
Revenue 1Y (TTM)8.81%
Revenue growth 3Y49.5%
Revenue growth 5YN/A
Revenue growth Q2Q-1.3%
3.2 Future
The Earnings Per Share is expected to grow by 16.02% on average over the next years. This is quite good.
Based on estimates for the next years, SKIN will show a small growth in Revenue. The Revenue will grow by 7.56% on average per year.
EPS Next Y-165.34%
EPS Next 2Y-51.93%
EPS Next 3Y16.02%
EPS Next 5YN/A
Revenue Next Year3.25%
Revenue Next 2Y6.79%
Revenue Next 3Y8.5%
Revenue Next 5Y7.56%
3.3 Evolution
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 20.19, the valuation of SKIN can be described as rather expensive.
Based on the Price/Earnings ratio, SKIN is valued a bit cheaper than 67.57% of the companies in the same industry.
The average S&P500 Price/Earnings ratio is at 24.67. SKIN is around the same levels.
SKIN is expected to report negative earnings next year, which makes the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 20.19 | ||
| Fwd PE | N/A |
4.2 Price Multiples
SKIN's Price/Free Cash Flow ratio is in line with the industry average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 45.82 | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as SKIN's earnings are expected to grow with 16.02% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-51.93%
EPS Next 3Y16.02%
5. Dividend
5.1 Amount
No dividends for SKIN!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
BEAUTY HEALTH CO/THE
NASDAQ:SKIN (4/30/2024, 7:24:17 PM)
After market: 3.23 0 (0%)3.23
0 (0%)
Chartmill FA Rating
GICS SectorConsumer Staples
GICS IndustryGroupHousehold & Personal Products
GICS IndustryPersonal Care Products
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap398.68M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 20.19 | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -10.77% | ||
| ROE | -168.55% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 48.49% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.43
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 12.43 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 6.07 | ||
| Quick Ratio | 5.28 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)-51.52%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y-165.34%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)8.81%
Revenue growth 3Y49.5%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y